

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 6185)

**RESIGNATION OF DIRECTOR
PROPOSED APPOINTMENT OF DIRECTOR
APPOINTMENT OF SENIOR MANAGEMENT
AND
CLOSURE OF REGISTER OF MEMBERS**

RESIGNATION OF DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Qiang XU (“**Mr. Xu**”) has tendered his resignation as a non-executive Director, with effect from the date of this announcement, due to his personal work arrangements.

Mr. Xu has confirmed that he has no disagreement with the Company and the Board, and there are no other matters relating to his resignation that need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to thank Mr. Xu for his valuable contributions to the Group during his tenure of office.

PROPOSED APPOINTMENT OF DIRECTOR AND APPOINTMENT OF SENIOR MANAGEMENT

Proposed Appointment of Director and Appointment of Chief Commercial Officer and Deputy General Manager

The Board is pleased to announce that, Ms. Jing WANG (“**Ms. Wang**”), who has been serving as the chief financial officer of the Group (the “**CFO**”) and the secretary of the Board (the “**Board Secretary**”), is nominated as a candidate for executive Director of the second session of the Board, and has been appointed as chief commercial officer and deputy general manager of the Group, with effect from the date of this announcement. She will be responsible for the management of overall commercial operation of the Group.

As a result of Ms. Wang’s new positions within the Group, Ms. Xi LUO (“**Ms. Luo**”) will succeed Ms. Wang as CFO and Mr. Jin CUI (“**Mr. Cui**”) will succeed Ms. Wang as Board Secretary, both with effect from the date of this announcement, details of which are set out in the sections headed “Appointment of Chief Financial Officer” and “Appointment of Board Secretary” below.

The biographical details of Ms. Wang are set out below:

Jing WANG (王靖), aged 41, is appointed as chief commercial officer and deputy general manager of the Group on September 10, 2021. Ms. Wang has been serving as a director of CanSino SPH Biologics Inc. (上海上藥康希諾生物製藥有限公司) (a subsidiary of the Company as of the date of this announcement) since February 2021. She has been serving as the CFO from March 2020 to September 2021, and as the Board Secretary from February 2017 to September 2021, where she was mainly responsible for corporate financing, financial management, corporate governance, and investor relations. Ms. Wang holds a bachelor's degree in economics, and a master's degree in engineering of Peking University. Ms. Wang has nearly 20 years of experience in the pharmaceutical industry. She has extensive experience in capital market operation, strategic financing, financial management, domestic and foreign marketing, corporate management, etc. After joining the Company in June 2012, Ms. Wang has led the establishment of the Group's financing, financial operations, human resource and administration systems as well as completing the pre-initial public offering fundraising of approximately RMB743 million. Ms. Wang successfully led the Company's initial public offering on the Main Board of the Hong Kong Stock Exchange in March 2019 and on the Sci-tech Innovation Board of the Shanghai Stock Exchange in August 2020, making the Company the first "A+H" dual listing vaccine company.

The nomination of Ms. Wang as an executive Director will be submitted to the Shareholders at the EGM (as defined below) for consideration and approval. The appointment of Ms. Wang as an executive Director will be effective upon the approval by the Shareholders at the EGM. Ms. Wang's term of office as an executive Director shall commence from the date of approval at the EGM until the expiry of the term of the second session of the Board. She shall be eligible for re-election upon the expiry of her term of office. The Company will enter into a service contract with Ms. Wang upon approval of her appointment at the EGM. Ms. Wang will not receive any director's fee or remuneration for serving as an executive Director from the Company.

Ms. Wang does not hold any directorships in any listed companies in the past three years prior to the date of this announcement. Save as disclosed above, Ms. Wang does not hold any positions in the Group, and does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company. As of the date of this announcement, Ms. Wang does not have any interest in the securities of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)). Ms. Wang has not been subject to any penalty or punishment imposed by the China Securities Regulatory Commission or any other relevant authorities or stock exchanges.

Save as disclosed above, Ms. Wang has confirmed that there is no other matter relating to her proposed appointment as Director and her appointment as chief commercial officer and deputy general manager of the Group that needs to be brought to the attention of the Shareholders, and there is no other information that needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange.

The Board extends its gratitude to Ms. Wang for her dedication, hard work and achievements made in the development of the Group during her tenure of office as CFO and Board Secretary, and believes that Ms. Wang will continue to make valuable contributions to the Group with her substantial leadership and management experience.

Appointment of Chief Financial Officer

The Board is pleased to announce the appointment of Ms. Luo as the CFO with effect from the date of this announcement. Ms. Luo will be responsible for financial management and capital operation, including the construction and management of group financial system and internal control system, enhancing the platform and broadening the channel of investment and financing, and decision on major operation activities and investment and financing, and provision of advice on compliance and corporate governance of listed companies and investor relations management.

The biographical details of Ms. Luo are set out below:

Xi LUO (羅樺), aged 44, is appointed as chief financial officer of the Group on September 10, 2021. Ms. Luo, Ph. D. of Micrological and Biochemical Pharmacology, graduated from China Union Medical College (中國協和醫科大學) (now known as Chinese Academy of Medical Sciences (中國醫學科學院)) in 2007. From May 2012 to March 2015, Ms. Luo worked as an analyst of medical health industry in Zhong De Securities Company Limited (中德證券有限責任公司). From March 2015 to September 2021, Ms. Luo worked as an executive director and deputy head of healthcare group of global investment banking committee in CITIC Securities Co., Ltd. (中信證券股份有限公司). During her tenure of office in CITIC Securities Co., Ltd., Ms. Luo participated in the Company's initial public offering on the Sci-tech Innovation Board of the Shanghai Stock Exchange in August 2020, making the Company the first "A+H" dual listing vaccine company. Ms. Luo has nearly 15 years of experience in brokerage research and investment banking, and projects she participated in involved IPO on Small and Medium-sized Board, IPO on the Sci-tech Innovation Board, IPO on GEM, refinancing of companies listed on Sci-tech Innovation Board, merger and acquisition, and corporate control transfer involving listed companies. Ms. Luo led and participated IPO, refinancing or merger and capital operation projects of Double Medical Technology Inc. (大博醫療科技股份有限公司) (a company listed on the Shenzhen Stock Exchange (stock code: 002901)), Sinocelltech Group Limited (北京神州細胞生物技術集團股份公司) (a company listed on the Sci-Tech Innovation Board of Shanghai Stock Exchange (stock code: 688520)), Sino Biological, Inc. (北京義翹神州科技股份有限公司) (a company listed on the Shenzhen Stock Exchange (stock code: 301047)), Joinn Laboratories (China) Co., Ltd. (北京昭衍新藥研究中心股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 603127) and the Hong Kong Stock Exchange (stock code: 006127)), Novogene Co., Ltd. (北京諾禾致源科技股份有限公司) (a company listed on the Sci-Tech Innovation Board of Shanghai Stock Exchange (stock code: 688315)), Changchun BCHT Biotechnology Co. (長春百克生物科技股份有限公司) (a company listed on the Sci-Tech Innovation Board of Shanghai Stock Exchange (stock code: 688276)), and Sansure Biotech Inc. (聖湘生物科技股份有限公司) (a company listed on the Sci-Tech Innovation Board of Shanghai Stock Exchange (stock code: 688289)), etc., with extensive experience in capital operations.

The Board believes Ms. Luo will make valuable contributions to the Group's further development as a leading biotech company with her substantial leadership and experience in capital market, and would like to take this opportunity to express its warmest welcome to Ms. Luo on her joining the Group and appointment as the CFO.

Appointment of Board Secretary

The Board is pleased to announce the appointment of Mr. Cui, the head of securities affairs department of the Group, as the Board Secretary with effect from the date of this announcement. Mr. Cui will be responsible for management of affairs in relation to capital market, investor relations management and assisting the Board in formulating development strategy in capital market and the formulation and implementation of capital operation projects during his term of office.

The biographical details of Mr. Cui are set out below:

Jin CUI (崔進), aged 34, is appointed as the Board Secretary on September 10, 2021. He also serves as the head of securities affairs department of the Company since October 2018 and the joint company secretary of the Company since March 2019. He joined the Company in May 2016 as the executive manager of corporate strategy department, primarily responsible for strategic research, business development and financial management. He has also been the assistant to the chief executive officer of the Company and was responsible for assisting the chief executive officer of the Company in the daily operation of business strategy from March 2017 to October 2018. Mr. Cui served as representative on securities matters from October 2018 to September 2021, where he was responsible for capital operations, information disclosure and assisting the secretary of the Board in investor relations. Mr. Cui served as an executive director of investment banking at Tianjin Branch of JZ Securities Co., Ltd. (九州證券股份有限公司) from August 2015 to April 2016. From June 2012 to July 2015, Mr. Cui worked at Tianjin Equity Exchange (天津股權交易所), where he was responsible for trading management and project management. Mr. Cui graduated from Tianjin University of Finance and Economics (天津財經大學) with a bachelor's degree in actuarial and risk management in June 2009. He obtained his master's degree in international financial analysis from University of Glasgow in December 2011.

The Board extends its gratitude to Mr. Cui for his dedication, hard work and achievements made in the development of the Group, and believes that Mr. Cui will continue to make valuable contributions to the Group with his substantial leadership and experience in investor relations and management of affairs in relation to capital market, and would like to take this opportunity to congratulate Mr. Cui on his promotion.

CLOSURE OF REGISTER OF MEMBERS

The Board hereby announces that the 2021 third extraordinary general meeting of the Company (the “**EGM**”) will be held at 2:00 p.m. on Monday, October 11, 2021 at No. 2 Ballroom, 2nd Floor, Hyatt Regency Tianjin East, No. 126 Weiguo Road, Hedong District, Tianjin, the People’s Republic of China, to consider and approve, among other things, the proposed appointment of Ms. Wang as an executive Director. A circular containing details of the proposed appointment will be despatched to the Shareholders in due course.

The register of members of the Company will be closed from Thursday, October 7, 2021 to Monday, October 11, 2021, both days inclusive, during which period no transfer of H shares will be registered, in order to determine the holders of the H shares of the Company who are entitled to attend and vote at the EGM.

To be eligible to attend and vote at the EGM, all properly completed transfer documents accompanied by the relevant share certificate(s) must be lodged with the Company’s H share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong no later than 4:30 p.m. on Wednesday, October 6, 2021 for registration.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, September 10, 2021

As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.